File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pharmacotherapy for obesity

TitlePharmacotherapy for obesity
Authors
KeywordsAnti-obesity drugs
Orlistat
Rimonabant
Sibutramine
Issue Date2009
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJCP
Citation
British Journal Of Clinical Pharmacology, 2009, v. 68 n. 6, p. 804-810 How to Cite?
AbstractObesity is associated with increased risk of conditions such as hypertension, dyslipidaemia, diabetes mellitus, and obstructive sleep apnoea. Pharmacotherapy for obesity should be considered in combination with lifestyle changes in obese patients, or overweight patients with other conditions that put them at risk of developing heart disease. Sibutramine and orlistat are the only two anti-obesity medications approved for long-term use. Sibutramine is a serotonergic and adrenergic drug that reduces food intake. Orlistat is a gastrointestinal lipase inhibitor that interferes with fat absorption. However, it commonly causes flatulence and diarrhoea. Rimonabant is the first of a series of endocannabinoid receptor antagonists. It was approved by the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMEA) as an adjunct to diet and exercise in treating obesity in 2006. However, despite the extensive clinical trial data, EMEA announced in 2008 that it has recommended suspension of rimonabant because of its psychiatric side effects. Studies evaluating the long-term safety and efficacy of anti-obesity agents are needed. © 2009 The British Pharmacological Society.
Persistent Identifierhttp://hdl.handle.net/10722/91674
ISSN
2015 Impact Factor: 3.83
2015 SCImago Journal Rankings: 1.486
PubMed Central ID
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorLi, Men_HK
dc.contributor.authorCheung, BMYen_HK
dc.date.accessioned2010-09-17T10:23:09Z-
dc.date.available2010-09-17T10:23:09Z-
dc.date.issued2009en_HK
dc.identifier.citationBritish Journal Of Clinical Pharmacology, 2009, v. 68 n. 6, p. 804-810en_HK
dc.identifier.issn0306-5251en_HK
dc.identifier.urihttp://hdl.handle.net/10722/91674-
dc.description.abstractObesity is associated with increased risk of conditions such as hypertension, dyslipidaemia, diabetes mellitus, and obstructive sleep apnoea. Pharmacotherapy for obesity should be considered in combination with lifestyle changes in obese patients, or overweight patients with other conditions that put them at risk of developing heart disease. Sibutramine and orlistat are the only two anti-obesity medications approved for long-term use. Sibutramine is a serotonergic and adrenergic drug that reduces food intake. Orlistat is a gastrointestinal lipase inhibitor that interferes with fat absorption. However, it commonly causes flatulence and diarrhoea. Rimonabant is the first of a series of endocannabinoid receptor antagonists. It was approved by the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMEA) as an adjunct to diet and exercise in treating obesity in 2006. However, despite the extensive clinical trial data, EMEA announced in 2008 that it has recommended suspension of rimonabant because of its psychiatric side effects. Studies evaluating the long-term safety and efficacy of anti-obesity agents are needed. © 2009 The British Pharmacological Society.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/BJCPen_HK
dc.relation.ispartofBritish Journal of Clinical Pharmacologyen_HK
dc.rightsThe definitive version is available at www.blackwell-synergy.com-
dc.subjectAnti-obesity drugsen_HK
dc.subjectOrlistaten_HK
dc.subjectRimonabanten_HK
dc.subjectSibutramineen_HK
dc.subject.meshAnti-Obesity Agents - adverse effects - pharmacology-
dc.subject.meshLactones - adverse effects - pharmacology-
dc.subject.meshLipase - antagonists and inhibitors-
dc.subject.meshObesity - drug therapy - metabolism-
dc.subject.meshPiperidines - adverse effects - pharmacology-
dc.titlePharmacotherapy for obesityen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0306-5251&volume=68&issue=6&spage=804&epage=810&date=2009&atitle=Pharmacotherapy+for+obesity-
dc.identifier.emailCheung, BMY:mycheung@hku.hken_HK
dc.identifier.authorityCheung, BMY=rp01321en_HK
dc.description.naturelink_to_OA_fulltext-
dc.identifier.doi10.1111/j.1365-2125.2009.03453.xen_HK
dc.identifier.pmid20002075-
dc.identifier.pmcidPMC2810792-
dc.identifier.scopuseid_2-s2.0-70849093104en_HK
dc.identifier.hkuros180002-
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-70849093104&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume68en_HK
dc.identifier.issue6en_HK
dc.identifier.spage804en_HK
dc.identifier.epage810en_HK
dc.identifier.isiWOS:000272171000002-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridLi, M=26661782700en_HK
dc.identifier.scopusauthoridCheung, BMY=7103294806en_HK
dc.identifier.citeulike6253411-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats